Cell primitive-based functional materials that combine the advantages of natural substances
and nanotechnology have emerged as attractive therapeutic agents for cancer therapy. Cell …

Cancer is one of the primary causes of worldwide human deaths. Most cancer patients
receive chemotherapy and radiotherapy, but these treatments are usually only partially …

In addition to increasing the expression of programmed death-ligand 1 (PD-L1), tumor cells
can also secrete exosomal PD-L1 to suppress T cell activity. Emerging evidence has …

Immunometabolic modulation offers new opportunities to treat cancers as it is highly
associated with cancer progression and immunosuppressive microenvironment. However …

Cancer vaccine, which can promote tumor-specific immunostimulation, is one of the most
important immunotherapeutic strategies and holds tremendous potential for cancer …

Utilizing neutrophils (NEs) to target and deliver nanodrugs to inflammation sites has
received considerable attention. NEs are involved in the formation and development of …

The high stability of antibodies and their ability to precisely bind to antigens and
endogenous immune receptors, as well as their susceptibility to protein engineering, enable …

Purpose: Given that heterogeneous expression and variants of antigens on solid tumors are
responsible for relapse after chimeric antigen receptor (CAR)-T cell therapy, we …

The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer
immunotherapy. However, despite great promise for a variety of cancers, the efficacy of …

Cancer immunotherapies, particularly therapeutic vaccination, do not typically generate
robust anti-tumour immune responses. Here, we show that the intratumoral burst release of …